Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The combined DNA integrity and replication machinery refers to the integrated network of proteins responsible for maintaining genomic stability during the S-phase of the cell cycle. This system coordinates the progression of the DNA replication fork with the DNA Damage Response (DDR) to ensure that DNA is accurately copied and repaired before cell division. Key components include master regulatory kinases such as ATR, ATM, and CHK1, as well as the replisome complex and various DNA repair enzymes like PARP. In cancer, this machinery is often deregulated, leading to chronic replication stress, which serves as a critical vulnerability that can be exploited by targeted therapies. Drugs targeting this system, such as PARP inhibitors and ATR inhibitors, aim to induce catastrophic DNA damage and apoptosis specifically in tumor cells that lack redundant repair pathways, a concept known as synthetic lethality.
Inhibition of checkpoint kinases (ATR, CHK1, WEE1) to induce replication fork collapse; PARP inhibition to trap DNA repair complexes; induction of lethal DNA damage through synthetic lethality.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA Damage Response and Replication Stress Machinery (DDR-RSR).